
Lannett Company LCI
Quarterly report 2023-Q1
added 05-15-2023
Lannett Company Cash Conversion Cycle 2011-2025 | LCI
Annual Cash Conversion Cycle Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 | 177 | 223 | 207 | 213 | 202 | 251 | 180 | 155 | 102 | 171 | 164 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 251 | 102 | 185 |
Quarterly Cash Conversion Cycle Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 | 168 | 168 | 82.9 | 168 | 177 | 174 | 94.1 | 194 | 171 | 204 | 188 | 205 | 228 | 257 | 251 | 204 | 177 | 221 | 193 | 194 | 186 | 212 | 54.9 | 120 | 110 | 114 | 113 | 126 | 123 | 85 | 156 | 175 | 155 | 180 | 128 | 139 | 115 | 84.3 | 70 | 108 | 157 | 139 | 121 | 146 | 165 | 152 | 146 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 257 | 54.9 | 156 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
327 | $ 0.66 | -0.02 % | $ 46.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
177 | $ 1.31 | -6.43 % | $ 141 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-58.9 | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
213 | $ 2.74 | -0.36 % | $ 1.44 B | ||
|
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
1.45 K | $ 4.57 | -1.72 % | $ 86.3 M | ||
|
Catalent
CTLT
|
110 | - | - | $ 11.5 B | ||
|
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
41.4 | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
181 | $ 12.63 | 0.72 % | $ 647 M | ||
|
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | ||
|
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
192 | $ 21.58 | 0.19 % | $ 2.05 B | ||
|
Evolus
EOLS
|
74.6 | $ 6.85 | 0.59 % | $ 425 M | ||
|
Harrow Health
HROW
|
-86.6 | $ 50.16 | 2.05 % | $ 1.64 B | ||
|
China Pharma Holdings
CPHI
|
164 | $ 1.31 | -1.5 % | $ 22.9 M | ||
|
Organogenesis Holdings
ORGO
|
64.5 | $ 5.87 | 2.09 % | $ 773 M | ||
|
Pacira BioSciences
PCRX
|
209 | $ 26.02 | 1.09 % | $ 1.2 B | ||
|
Bausch Health Companies
BHC
|
78.9 | $ 7.18 | -1.91 % | $ 2.62 B | ||
|
OrganiGram Holdings
OGI
|
2.92 K | $ 1.76 | 1.15 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-161 | $ 4.2 | -1.41 % | $ 59.1 M | ||
|
Rockwell Medical
RMTI
|
45 | $ 0.81 | -0.81 % | $ 18.9 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
150 | $ 3.64 | 1.68 % | $ 4.52 M | ||
|
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
-21.1 | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
138 | $ 13.75 | 0.51 % | $ 1.89 B | ||
|
ProPhase Labs
PRPH
|
96 | $ 0.62 | -10.48 % | $ 9.82 M | ||
|
Veru
VERU
|
6.7 | $ 2.34 | 0.86 % | $ 316 M | ||
|
Radius Health
RDUS
|
-53.5 | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
92 | $ 1.59 | -4.22 % | $ 6.86 M | ||
|
SCYNEXIS
SCYX
|
106 | $ 0.6 | 1.78 % | $ 28.7 M | ||
|
Tilray
TLRY
|
169 | $ 10.15 | -3.61 % | $ 6.27 B | ||
|
TherapeuticsMD
TXMD
|
-723 | $ 1.7 | 3.66 % | $ 17.7 M | ||
|
Zomedica Corp.
ZOM
|
196 | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
155 | $ 12.24 | 1.83 % | $ 14.8 B |